NewAmsterdam Pharma Company NV NAMS

NL Biotechnology

$23.81 ▲ +0.98% (+$0.23)

🔥 High Short Interest

Open $23.52

Prev Close $23.58

Day Range $23.26 – $24.54

52W Range $21.02 – $42.21

Market Cap $2.85B

Beta 0.11

EPS (TTM) $-2.15

📋 Company Profile

Industry	Biotechnology
Country	NL
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2022-11-23
Shares Out.	116,900,000
Website	ir.newamsterdampharma.com/ ↗
Phone	31352062971
Employees	100
Revenue	$3.7M
Gross Profit	$3.7M
Net Income	-$64.1M
Free Cash Flow	-$143.7M
Total Assets	$704.5M
Total Liabilities	$73.0M
Equity	$631.4M

About NewAmsterdam Pharma Company NV

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

NewAmsterdam Pharma Company NV is a publicly traded company under the ticker symbol NAMS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.